The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Oral Mucositis by 13 companies/universities/institutes. The top development phase for Oral Mucositis is preclinical with seven drugs in that stage. The Oral Mucositis pipeline has 13 drugs in development by companies and two by universities/ institutes. Some of the companies in the Oral Mucositis pipeline products market are: GlycoMira Therapeutics, Destiny Pharma and Clevexel Pharma.
The key targets in the Oral Mucositis pipeline products market include P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP), NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3), and Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1).
The key mechanisms of action in the Oral Mucositis pipeline product include P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) Inhibitor with two drugs in Preclinical. The Oral Mucositis pipeline products include eight routes of administration with the top ROA being Oral and two key molecule types in the Oral Mucositis pipeline products market including Small Molecule, and Recombinant Protein.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Oral Mucositis overview
Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy, and radiation. Symptoms include change in mucosa color, hyposalivation, a change in the integrity of the mucosa, and the presence of edema on the lips and/or the tongue. Treatment includes oral decontamination (mouth care) and oral debridement.
For a complete picture of Oral Mucositis’s pipeline drug market, buy the report here.
Source link
#Oral #Mucositis #drugs #development
